Clinical Trial Update: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a combination of vismodegib, defactinib, capivasertib, and abemaciclib for intracranial or recurrent meningioma, including NF2-mutant c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningioma
• Neurofibromatosis Type

Drugs mentioned

• Abemaciclib (Verzenio) (abemaciclib)
• Capivasertib (AZD5363) (capivasertib)
• Vismodegib (Erivedge) (vismodegib)
• defactinib (GSK2256098) (defactinib)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Intracranial Meningioma, Recurrent Meningioma | Phase 2 | Status: RECRUITING